Tipranavir - Generic Drug Details

What are the generic drug sources for tipranavir and what is the scope of patent protection?

Tipranavir is the generic ingredient in one branded drug marketed by Boehringer Ingelheim and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for tipranavir. One supplier is listed for this compound.

Summary for tipranavir

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	2
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	61
Clinical Trials:	68
What excipients (inactive ingredients) are in tipranavir?	tipranavir excipients list
DailyMed Link:	tipranavir at DailyMed

Recent Clinical Trials for tipranavir

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cairo University	N/A
Aswan Heart Centre	N/A
Rockefeller University	Phase 4

See all tipranavir clinical trials

Pharmacology for tipranavir

Drug Class	Protease Inhibitor
Mechanism of Action	HIV Protease Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for tipranavir

J05AE	Protease inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for tipranavir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	APTIVUS	tipranavir	CAPSULE;ORAL	021814-001	Jun 22, 2005		RX	Yes	Yes
Boehringer Ingelheim	APTIVUS	tipranavir	SOLUTION;ORAL	022292-001	Jun 23, 2008		DISCN	Yes	No

EU/EMA Drug Approvals for tipranavir

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Aptivus	tipranavir	EMEA/H/C/000631Aptivus, co-administered with low-dose ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infection in highly pretreated adults and adolescents 12 years of age or older with virus resistant to multiple protease inhibitors.Aptivus should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.This indication is based on the results of two phase-III studies, performed in highly pretreated adult patients (median number of 12 prior antiretroviral agents) with virus resistant to protease inhibitors and of one phase-II study investigating pharmacokinetics, safety and efficacy of Aptivus in mostly treatment-experienced adolescent patients aged 12 to 18 years.In deciding to initiate treatment with Aptivus, co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of Aptivus. Initiation of treatment should take into account the combinations of mutations which may negatively impact the virological response to Aptivus, co-administered with low-dose ritonavir.	Authorised	no	no	no	2005-10-25

Market Dynamics and Financial Trajectory for Tipranavir

Last updated: February 14, 2026

Overview

Tipranavir is an antiretroviral protease inhibitor used to treat HIV-1 infections. Manufactured by Boehringer Ingelheim, it was approved by the U.S. Food and Drug Administration (FDA) in 2005. Its primary indication is for salvage therapy in patients with multidrug-resistant HIV. The drug's market presence has diminished over time due to the advent of newer antiretroviral therapies with improved safety profiles.

---

Market Landscape and Competitive Position

Historical Market Share

• Peak sales occurred between 2006 and 2008, driven by adherence to guidelines for multidrug-resistant HIV treatment.
• In 2008, global sales reached approximately $150 million.
• Post-2008, sales declined sharply, influenced by exigent competition.

Active Market Segments

• Primarily used in salvage therapy for patients with resistance to other protease inhibitors.
• Limited use in first-line regimens—superseded by integrase inhibitors and newer agents with better tolerability.

Competitive Environment

• Competition from drugs like darunavir, atazanavir, and newer agents such as dolutegravir.
• Availability of genotypic resistance testing influences prescribing practices, often favoring newer, more tolerable drugs.

Patent and Regulatory Status

• Patent expiry in many regions around 2015.
• Limited pipeline development; no recent filings or new formulations announced [1].

---

Market Challenges

• Declining demand due to efficacy and safety profile concerns.
• Shift towards treatment regimens with fewer side effects.
• Reduced reimbursement and formulary placements as newer drugs gain approval.

Pricing Dynamics

• Original pricing ranged from $50,000 to $70,000 annually per patient.
• Price erosion observed post-patent expiry.
• Market access hindered by affordability issues in lower-income regions.

---

Financial Trajectory

Year	Estimated Global Sales (USD Millions)	Notes
2006	100–150	Peak sales year
2008	150	Highest recorded sales
2010	70	Decline begins
2015	20–30	Patent expiry influence
2018	<10	Market largely phased out
2020–2023	Minimal (<1)	Rare off-label use or salvage cases

Revenue Forecast

• Sales projected to stay minimal, with negligible revenue beyond 2023.
• No active pipeline or developmental activity reported; unlikely to revive commercial interest.

---

Regulatory and R&D Outlook

• No recent regulatory filings for new formulations or indications.
• Limited prospects for reformulation or combination products.
• R&D focus shifted to novel antiretrovirals with better safety profiles and delivery mechanisms.

---

Summary of Market Drivers and Limitations

Drivers	Limitations
Existing use in salvage therapy	Obsolescence due to new drugs
Historical market presence	Patent expiry, generic entry
Resistance testing favoring existing drugs	Safety and tolerability issues

---

Key Takeaways

• Tipranavir's market peaked in the late 2000s, with sales declining sharply due to competition and newer treatment options.
• Its primary use remains in salvage therapy for severely resistant HIV cases.
• Patent expiry and safety concerns have rendered the drug largely obsolete.
• The current financial outlook is negligible, with no recent development efforts.
• Market dynamics favor newer agents, and tipranavir's role is confined to niche cases.

---

FAQs

1. Why did tipranavir sales decline after 2008?
Sales declined due to competition from newer, more tolerable protease inhibitors and integrase inhibitors, along with an evolving treatment landscape favoring drugs with fewer adverse effects.

2. Is tipranavir still used today?
Limited to severe, multidrug-resistant HIV cases where other options are exhausted, reflecting a niche application rather than mainstream therapy.

3. Are there any plans to develop new formulations of tipranavir?
No active development or regulatory filings are in progress according to current patent and clinical trial databases.

4. How does tipranavir compare price-wise with newer HIV drugs?
Initially priced around $50,000–$70,000 annually per patient, but prices have eroded significantly due to generic competition and market shifts.

5. What strategic options exist for companies with patents on tipranavir?
Potential strategies include licensing expired patents for niche or orphan indications, or developing combination therapies, though no such initiatives are currently documented.

---

Sources

[1] FDA Drug Approval Database (2005).
[2] Boehringer Ingelheim Annual Reports (2006–2023).
[3] IMS Health Sales Data (2006–2018).